Skip to main content
. 2013 Apr 28;2013:705714. doi: 10.1155/2013/705714

Figure 2.

Figure 2

Survival of patients achieving an antileukemic effect or stable response compared with that of patients showing disease progression. Patients for whom an anti-leukemic effect was observed had a mean duration of survival that doubled the one of those with a bortezomib fully insensitive disease (4 months versus 2 months; P = 0.031).